2022 American Transplant Congress » Viral Hepatitis
Date: Tuesday, June 7, 2022
Time: 5:30pm-7:00pm
Location: Hynes Room 312
Session Type: Rapid Fire Oral Abstract
Meeting: 2022 American Transplant Congress
- 5:30pm-5:40pm
Current State of Use of Hepatitis C Viremic Donor Organs in Negative Recipients in the United States: A National Survey
K. Ryland1, K. Hattori2, J. Steinbrink3, N. Theodoropoulos4, M. Ison5
- 5:40pm-5:50pm
Expanded Experience with Ultra-Short Duration Pangenotypic Direct Acting Anti-Viral (DAA) Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic (HCV) Donors to Hepatitis C Negative Kidney Transplant Recipients (KT)
I. Yakubu, D. Kumar, A. Sharma, M. Levy, L. Kamal, G. Gupta
- 5:50pm-6:00pm
Decision-Making Among HCV-Negative Transplant Candidates Offered Organs from Donors with HCV Infection
E. Schnellinger1, E. Saine1, M. Liu1, J. Diamond1, M. Crespo1, S. Prenner1, V. Potluri1, C. Bermudez1, H. Mentch1, M. Moore2, B. Besharatian1, D. Goldberg3, F. Barg1, P. Reese1
- 6:00pm-6:10pm
Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population
A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran
- 6:10pm-6:20pm
National Consortium Registry Insights on Management and Outcome of Hepatitis C Viremic Heart Transplants
R. Gottlieb1, M. Salem1, A. Ravichandran2, J. Kennedy3, J. Strope4, S. Lin5, J. Chow6, P. Eckman7, S. Desai8, O. Larkins1, J. Vanzyl1, S. Hall1
- 6:20pm-6:30pm
Hypothermic Pulsatile Flush of Hepatitis C Virus (HCV) RNA Positive Kidney Reduces Viral Load
A. Jain1, W. Greene2
- 6:30pm-6:40pm
Variable Course of Hepatitis A Virus Infection in Solid Organ Transplant Recipients
A. Vostal1, J. Husson2, A. Shishido1, N. Jakhete3, E. Moore4, X. Wen5, A. Amoroso2, R. Meier6, E. Wilson2, K. K. Saharia2
- 6:40pm-6:50pm
Management of Hepatitis B Positive Donors in Liver Transplant
M. Tilley1, T. A. Sparkman2, K. Gutierrez2
- 6:50pm-7:00pm
Safety and Efficacy at 4 Years in Post-Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide (TAF) for HBV Prophylaxis
E. Gane1, B. George1, D. Ray-Chaudhuri1, T. Mules1, C. D. Holt2, H. Wang2, V. Suri2, A. Gaggar2, A. Osinusi2, J. Flaherty2
« View all sessions from the 2022 American Transplant Congress